Vincristine sulfate

Catalog No.S1241 Synonyms: Leurocristine

Vincristine sulfate Chemical Structure

Molecular Weight(MW): 923.04

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Plk inhibitor cooperates with chemotherapeutic agents. Conditional patched mutant tumor cells were treated with increasing concentrations of the chemotherapeutic agents vincristine alone or in combination with 10 nMol/L BI-2536. Cells were cultured for 48 hours, pulsed with 3H-Td, and harvested for analysis of 3H-Td incorporation at 66 hours.

    Cancer Research, 2013, 73(20): 6310-22 . Vincristine sulfate purchased from Selleck.

    for HXO-RB44 cells, IC50 values for VCR were changed in the different SG600 treatment groups. The results are representative of three independent  experiments and of f our replicates in each experiment.

    Int J Mol Sci 2012 13, 10736-10749 . Vincristine sulfate purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.
Targets
Microtubules [1]
(Cell-free assay)
32 μM
In vitro

Vincristine inhibits net addition of tubulin dimers at assembly ends of steady-state microtubules with Ki of 85 nM. [1] At low concentrations, Vincristine stabilizes the spindle apparatus resulting in failure of the chromosomes to segregate leading to metaphase arrest and inhibition of mitosis. At higher concentrations, Vincristine may disrupt and induce total depolymerization of microtubules. [2] Vincristine induces apoptosis in tumor cells and inhibits SH-SY5Y cell proliferation with IC50 of 0.1 μM. Vincristine induces mitotic arrest and promots the expression of caspase-3 and -9 and cyclin B, while decreasing the expression of cyclin D. [4] Vincristine induced neurotoxicity is caused by interference with microtubule function, which results in blockage of axonal transport and thus in axonal degeneration. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2.2.15 NX\iOnJyS2WubDDWbYFjcWyrdImgRZN{[Xl? NF;mV44xNTBwNTFOwG0> M36wWFI1KGh? MmTR[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? M3qxSFI2PjZ|N{[5
HepG2-HBV1.1 Ml;6RZBweHSxc3nzJGF{e2G7 MV6wMVAvPSEQvF2= MX2yOEBp M3\Meolv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm= MU[yOVY3Ozd4OR?=
HepG2.2.15 NXXDOYRDTnWwY4Tpc44hSXO|YYm= NYnWVWpWOC5zIN88US=> M3z4WFI1KGh? M{LSbJBzd22xdHXzJIhmeGG2aYTpd{BDKH[rcoXzJJBzd3SnaX6g[ZhxemW|c3nvci=> NYLK[Is5OjV4NkO3Olk>
HepG2-HBV1.1 MU\GeY5kfGmxbjDBd5NigQ>? Mn\wNE4yKM7:TR?= MkDNNlQhcA>? M{jIVJBzd22xdHXzJIhmeGG2aYTpd{BDKH[rcoXzJJBzd3SnaX6g[ZhxemW|c3nvci=> MWGyOVY3Ozd4OR?=
HepG2-HBV1.1 NF7wWZlHfW6ldHnvckBCe3OjeR?= M17pc|AvOSEQvF2= NVz1bHFRPDhiaB?= MWXwdo9ud3SnczDj[YxtKGW6Y4LleIlwdiCxZjDo[ZBifGm2aYOgRkB3cXK3czDueYNt\W:lYYDzbYR{KGmwc4TlZYQhd2ZiaHXwZZRqfGm|IFKgeolzfXNiRHHu[UBx[XK2aXPs[ZM> NF74fHczPTZ4M{e2PS=>
HepG2-HBV1.1 NVv3S3lST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX6wMlEh|ryP NV[y[WxGOS13IHS= MlvNbY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36geIlu\SCmZYDlcoRmdnSueR?= M2S0NVI2PjZ|N{[5
HepG2-HBV1.1 NF\aUY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXKwMlEh|ryP NFT4XokyNTViZB?= MYfpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjD0bY1mKGSncHXu[IVvfGy7 MoPtNlU3PjN5Nkm=
HepG2-HBV1.1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkO1NE4yKM7:TR?= NXT4c2ZHOTJvN{KgbC=> NH\OTGVqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KFNvcHjhd4U> M3OwV|I2PjZ|N{[5
HepG2-HBV1.1 NEXS[JpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHZcJIxNjFizszN MUWxNk04OiCq MX7pcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHH0JHMueGijc3W= MWGyOVY3Ozd4OR?=
Raji MnixSpVv[3Srb36gRZN{[Xl? NUXyS4M3OC53wrFOwG0> MVi3NkBp MkjhZYJwdGm|aHXzJIF2fG:yaHHnfeKh MXSyOVQ1PjN5Nx?=
SK-MEL-28  MkLJSpVv[3Srb36gRZN{[Xl? MYKzNEBvVQ>? NGjJXZk3KGh? MofybY5lfWOnczDHNwKBm01iY3XscE1kgWOuZTDhdpJme3R? MmjXNlU{OTNyMUC=
H157 NFHJNYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml23TWM2OD1zLkCzJOKyKDBwMESgcYl2Ok1? NX;ne|Q1OjV{NUe5NVE>
Jurkat NFPINHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEL3cXUyNTNibl2= NV22R2R{PDkEoHi= MWTEUXNQ NYXYcGFF\GWlcnXhd4V{KH[rYXLs[UBk\WyuIH71cYJmenNiZH;z[UBl\XCnbnTlcpRtgQ>? NHfCW2MzPTF3NkG0Oi=>
CEM NUPtSFY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYixMVMhdk1? MkLJOFjDqGh? MVTEUXNQ Mn30[IVkemWjc3XzJJZq[WKuZTDj[YxtKG63bXLldpMh\G:|ZTDk[ZBmdmSnboTsfS=> M1naXVI2OTV4MUS2
P12 NXfUbWtVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HuPVEuOyCwTR?= NXX4WHhtPDkEoHi= NWjzXVNiTE2VTx?= NYrjZ2Yy\GWlcnXhd4V{KH[rYXLs[UBk\WyuIH71cYJmenNiZH;z[UBl\XCnbnTlcpRtgQ>? Ml76NlUyPTZzNE[=
KB NWfGXpBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzVTWM2OD1yLkCwOFkhyrFiMD6wNFAyKM7:TR?= NFTYUlUzPTB3OEWyOi=>
KBv200 (ABCB1) NFqzfXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGj1OWFKSzVyPUCuN|Q3OiEEsTCwMlAxPjZizszN NUXCZWxYOjVyNUi1NlY>
SUDHL6  MnjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7uRXlROeLCid88US=> M1rx[VQ5Nzd{IHi= NW\jZWM2cW6qaXLpeJMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? M1HPOFI1QTZzNkC0
SUDHL6  MVTGeY5kfGmxbjDBd5NigQ>? NGrsXnUy6oDLzszN NEHKcHM4OiCq MlnsbY5lfWOnczDzbYdvcW[rY3HueEBieG:ydH;0bYMhdW:{cHjvcI9ogSClaHHu[4V{KGOxdILld5Rm\CC5aYToJGJEVDFzQTDzbXJPSQ>? MVyyOFk3OTZyNB?=
HCT-116 NV\qOYNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHHTVUxRTVibl2= NYjGXG9iOjR7Mke4OVc>
SKNBe2C MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3j1TWlEPTB;M{KuPOKyPC5yIH7N NULNPG1KOjR7MkG5NlA>
IGNR91 M1TDeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jQb2lEPTB;MkSuN:KyOS55IH7N M3S0elI1QTJzOUKw
SKNAS NF7ZRlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIraXVBKSzVyPUGuOeKyOC5{IH7N NVvSbFVLOjR7MkG5NlA>
LAN1 NHXkb4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PQZ2lEPTB;Mj6zxtExNjJibl2= NH3QXGMzPDl{MUmyNC=>
SHSY5Y MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRThwMtMxNE43KG6P MlnFNlQ6OjF7MkC=
A549-WT M{CzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PKV2lEPTB;MUmuOFM4KMLzIECuOVk1KCCwTR?= NYjQUHUxOjR6NUi4Nlc>
A549-R M1q0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPIe2hVUUN3ME2xNk4yPzhiwsGgNE4{OzNiIH7N M4[zXlI1QDV6OEK3
MCF-7-WT M3rCSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTF5Lke1NkDDuSByLkKxPEAhdk1? NVzsVWJSOjR6NUi4Nlc>
MCF-7-R M4L5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXixWJNuUUN3ME21MlU{QSEEsTCwMlE1PCBibl2= NHfuSFgzPDh3OEiyOy=>
A549-R NGXUVYVEgXSxdH;4bYNqfHliQYPzZZk> NGLwOI9KSzVyPUGyMlE4QCEEsTCwMlM{OyCwTR?= NImxSIUzPDh3OEiyOy=>
MCF-7-R MULDfZRwfG:6aXPpeJkhSXO|YYm= MUjJR|UxRTVwNUO5JOKyKDBwMUS0JI5O NGHsU|czPDh3OEiyOy=>
SW620 NVrXXWZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTqNVlKSzVyPUeuPFAhyrFiMD6wPEBvVQ>? NWDRS3ViOjR5Mk[3N|k>
SW620/AD300 MnezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\2TWM2OD17MEmuOlAhyrFiOD65NUBvVQ>? NEDRdIgzPDd{NkezPS=>
HEK293/pcDNA3.1 MlvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PRZmlEPTB;MT60OUDDuSByLkKwJI5O M4OwPFI1PzJ4N{O5
HEK293/ABCC1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDEWnlKSzVyPUG5MlI6KMLzIEKuNFghdk1? Mo\iNlQ4OjZ5M{m=
TCC M3\PXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEj4UFczPCCq Mo\yTWM2OD15MDDuUS=> NYD3VmZ[OjR5MU[5OFQ>
TCC MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\zNnc1QCCq MYTJR|UxRTVyIH7N NHvmNGkzPDdzNkm0OC=>
HepG2/ADM NW\PV3pqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTJwN{i2N:KyOC5{M{exJO69VQ>? Mlv6NlQ4ODR3NU[=
HepG2 Mon6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\mTnVvUUN3ME2wMlAyOTYEsUCuNFAyPyEQvF2= NVK0fJBmOjR5MES1OVY>
MCF-7/ADR MlfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIH4VldKSzVyPUSuOFgzPsLzMD6yNFcxKM7:TR?= NVrHNZBVOjR5MES1OVY>
MCF-7 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVyzZ5NMUUN3ME2wMlAyPToEsUCuNFA3OiEQvF2= M1;hSFI1PzB2NUW2
A-172  MoS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPxNE4yyqEQvF2= MUGyOE84OiCq NHvBNlVqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lJIRmeGWwZHXueIx6 MnrVNlQ2OzB{M{W=
U-251MG MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYWwMlHDqM7:TR?= NGewXo4zPC95MjDo NWjVO3FqcW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBl\XCnbnTlcpRtgQ>? MVqyOFU{ODJ|NR?=
DLD-1 Mmm2SpVv[3Srb36gRZN{[Xl? MVSxNFAhdk1? NVzyc3NkPDhiaB?= M2rwbJBzd22xdHXzJHJWVlh|IHTlcYV1cHmuYYTpc47DqA>? M4LtV|I1PDB|NEWz
CCD18Co M3;0O2Z2dmO2aX;uJGF{e2G7 Mkn3NVAxKG6P NXu5W2dbPDhiaB?= MkXsdJJwdW:2ZYOgVnVPYDNiZHXt[ZRpgWyjdHnvcuKh NEDrfWgzPDRyM{S1Ny=>
DLD-1 M17rbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW[wMVExODBibl2= NVroSGhbPDhiaB?= MXjpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MVKyOFQxOzR3Mx?=
CCD18Co NXfXOVVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{WxbFAuOTByMDDuUS=> NInsPFc1QCCq NGfYXoFqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NX3yUpFZOjR2MEO0OVM>
HepG2 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYOyOEBp MmG2TWM2OD13Mj615qCK|ryP M{j3OFI1OzRzNki4
HEK293/pcDNA3.1 NETvZ3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTnPYJKSzVyPUCuNFA1yrFyLkCwNFMh|ryP NHTiWIUzPDJ6NEe4Ny=>
HEK293/MRP1 MoHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYL4SXJvUUN3ME2wMlA2PcLzMD6wNVIxKM7:TR?= NVzrR3l7OjR{OES3PFM>
Ramos Mn;wRZBweHSxc3nzJGF{e2G7 M1zGT|LjiIoQvF2= M{DmV|Q5KGh? NGm1[FlqdmS3Y3XzJFM1NjZnwsGxMlkzLSCjcH;weI9{cXN? Mn3INlQzPTZ2OUG=
NCI-H1299/pcDNA3 M33iSGNmdGxiVnnhZoltcXS7IFHzd4F6 NHf6VGcxNTJyIH7N MnLSPVYhcA>? NIDCWFZqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NVjXPFluOjRzN{ewNVI>
H1299/ICAM-3 MYPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MlLHNE0zOCCwTR?= NUHKcmc{QTZiaB?= NIm4OGRqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NIH6O3kzPDF5N{CxNi=>
NCI-H1299/pcDNA3 M{HzbGZ2dmO2aX;uJGF{e2G7 MX2xM|UwOTBxMkFCpI5O NHiyb4w6PiCq NVrpS2hCcW6mdXPld{BkdGWjdnHn[UBw\iClYYPwZZNmey1|LDC4MEA6NCCjbnSgVGFTWA>? MoS1NlQyPzdyMUK=
H1299/ICAM-3 MWDGeY5kfGmxbjDBd5NigQ>? NE[1W|cyNzVxMUCvNlDDqG6P NFX6TpQ6PiCq MX7pcoR2[2W|IHPs[YF3[WenIH;mJINie3Cjc3XzMVMtKDhuIEmsJIFv\CCSQWLQ MmrJNlQyPzdyMUK=
W1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLLTWM2OD1yLkCwN|Ih|ryP M37JeVI1OTRyMUe2
W1VR NGHERY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTBwMEW2JO69VQ>? M1;ieVI1OTRyMUe2
K562 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\0UlFKSzVyPUCuNFMzKMLzIECuNFAyKCEQvF2= NGjXb2YzPDF|NUmzOy=>
K562/ADR M1;kR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTNwMk[xJOKyKDBwNEGyJO69VQ>? NI\0NVUzPDF|NUmzOy=>
K562 MlztRZBweHSxc3nzJGF{e2G7 M2e0V|AvOyEQvF2= NUjueGhnOjRiaB?= M4r4Tolv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl? NXrwPJR3OjRzM{W5N|c>
K562/ADR NIHvT21CeG:ydH;zbZMhSXO|YYm= MVWzJO69VQ>? NHr4VG4zPCCq NGTOeI5qdmS3Y3XzJIFxd3C2b4Ppdy=> Ml\ENlQyOzV7M{e=
A549 M3n4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwMUCgxtEhOC5yMzFOwG0> MkPJNlM6PzFyN{W=
K562 NYn2elkyS2WubDDWbYFjcWyrdImgRZN{[Xl? MV[zMlc26oDVNkFCpI5O NFPNfWE4OsLiaNMg NET5ZmFqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NXmyNIpsOjN6N{eyNlM>
lucena M4fIbWNmdGxiVnnhZoltcXS7IFHzd4F6 NHSxfog{Njd34pETOlDDqG6P M3\p[lczyqCqwrC= M{jIVo5wKGWoZnXjeC=> MWiyN|g4PzJ{Mx?=
FEPS NGrsWVlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NYe4SJF[Oy55NfMAl|YxyqCwTR?= MXi3NuKhcMLi MVHuc{Bm\m[nY4S= MoTyNlM5Pzd{MkO=
A2780 M4qyNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG[1OYNKSzVyPUOuOUBuVQ>? MkLUNlM5Ojl{MEO=
ACHN MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXLbGl2UUN3MEywMlEhdU1? MkTJNlM5Ojl{MEO=
U-937 M2XXS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoThTWM2ODx|NDDuUS=> MWWyN|gzQTJyMx?=
Jurkat M3XUOWFxd3C2b4Ppd{BCe3OjeR?= NVX0SpFvPcLizsznM41tyqB? Ml;RNlQhcA>? MUHpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 NEfTcXEzOzhzMESwPS=>
Jurkat M2ToVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfoeXI2yqEQvHevcYzDqA>? NVnuZmdKOjRiaB?= MlnLZZJz\XO2IFr1dotifCClZXzsd{BqdiCJMj;NJJBp[XOn NUnWWWJOOjN6MUC0NFk>
Hep-2 Mn2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwMEVCtVAvODFizszN NX7Bc2d{OjN5OEC0NlQ>
Hep-2/v M1TSUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jmRmlEPTB;MT64xtExNjJyIN88US=> MWOyN|c5ODR{NB?=
SGC-7901 M2LhV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm[2NE0yOCEQvHevcYw> NUHteXk3OjRxNEivO|IhcA>? MkjxbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy NXu2WZF[OjN5NEO1O|I>
SGC-7901/VCR M4rlXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXGNE0yOCEQvHevcYw> NUjveFRFOjRxNEivO|IhcA>? NFPreGZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> NHf2em4zOzd2M{W3Ni=>
SGC-7901 NV;B[FlRSXCxcITvd4l{KEG|c3H5 Mk\jbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgQ>? NGS2bIczOzd2M{W3Ni=>
SGC-7901/VCR M1j5eGFxd3C2b4Ppd{BCe3OjeR?= MmLVbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgQ>? NETud40zOzd2M{W3Ni=>
KB-3-1 M1vRdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mli5TWM2OD1zLk[2JOKyKDBwMU[yJO69VQ>? NGflboczOzZ5M{S0OS=>
KB-C2 MnLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\HTWM2OD1{MEKuOVYhyrFiNEKuOFgyKM7:TR?= NGjET4YzOzZ5M{S0OS=>
KB-3-1 M3rJWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDTcoVKSzVyPUGuNlYhyrFiMD6wNlch|ryP M33kSlI{Pjd|NES1
KB-V1 M37tN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfZb3RTUUN3ME2yNFgvQDViwsGgNlAvPCEQvF2= MljNNlM3PzN2NEW=
HEK293/pcDNA3.1 M{nxZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTJ2LkGgxtEhOC5{MESg{txO M3PpSVI{Pjd|NES1
HEK293/ABCB1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TISGlEPTB;M{WxNk45KMLzIEO3PE4{QTFizszN NYHDb2M1OjN4N{O0OFU>
A549/EGFP  NHGweI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljsNE4xOS1zMECwJO69VQ>? NY[0cZpUUUN3ME24Ok44KMLzIEK5MlEh|ryP NYKxPGw2OjN4M{SyPFI>
A549/Slug MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUWwMlAyNTFyMECg{txO MlTUTWM2OD17LkegxtEhOy5zIN88US=> NFPqfnYzOzZ|NEK4Ni=>
JFCR39  M171PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4X2eVEhyrWP M2XqdFI1KGh? M13LVGROW09? MXjtZZJs\WSueTDpcoNz\WG|ZYOgeIhmKG63bXLldkBw\iCJMj;NJJBp[XOnIHPlcIx{ NGDsPJMzOzV7OEK3Oi=>
A549 M33XNGZ2dmO2aX;uJGF{e2G7 M1\hUlExOCCwTR?= NHHLVJUyPiCq NHnYV|FFVVOR M1LZWoxm[WS|IITvJIEhdG:|czDv[kBucWO{b4T1ZpVt\XN? MX2yN|U6QDJ5Nh?=
SGC7901 NGDTV|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPaTWM2OD1zLkK25qCKyrIkgJmwMlEyKM7:Zz;tcC=> NUPrWJNLOjN3NkS0PFI>
SGC7901/LV-NC MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkL3TWM2OD1zLke35qCKyrIkgJmwMlE3KM7:Zz;tcC=> NHT2SIMzOzV4NES4Ni=>
SGC7901/LV-SGO1 NIPL[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXhTWM2OD12LkO25qCKyrIkgJmwMlM4KM7:Zz;tcC=> M2LlOVI{PTZ2NEiy
SGC7901/VCR MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkL4TWM2Oz1{MD61N-KBkcLz4pEJNU46PiEQvHevcYw> M12wOVI{PTZ2NEiy
SGC7901/VCR-NC MlW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1H0VWlEPTB;MUmuPFbjiIoEsfMAjVIvODFizsznM41t NWj1NHMxOjN3NkS0PFI>
SGC7901/VCR-si-SGO1 NGXuXJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXG3dGZ4UUN3ME22MlE56oDLwsJihKkyNjB|IN88[{9udA>? NHTFU4czOzV4NES4Ni=>
SGC7901/ADR NYrFTYRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rISGlEPTB;Nz64OgKBkcLz4pEJNE43PCEQvHevcYw> NX\s[WhIOjN3NkS0PFI>
SGC7901/ADR-NC NG\PcJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUKwPWdOUUN3ME24Mlk{6oDLwsJihKkxNjZ6IN88[{9udA>? M3q5blI{PTZ2NEiy
SGC7901/ADR-si-SGO1 M4fQPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlW1TWM2OD1|LkS25qCKyrIkgJmwMlI6KM7:Zz;tcC=> NXTVPW1xOjN3NkS0PFI>
SH-SY5Y  M{nRXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXK5VZpQOC5yMEGtNVAh|ryP MXeyOEBp NWLCUoZkUUN3ME2wMlEyO8LzMD6wNVIh|ryP MonXNlMyOjlyNkW=
SH-SY5Y  NVjZNmxGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWGwMlAxOS1zMDFOwG0> MUS0PEBp Ml;2TWM2OD1yLkC3POKyOC5yMEmg{txO MmH3NlMyOjlyNkW=
SH-SY5Y  NGH3VYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXKwMlAxOS1zMDFOwG0> NGm4d3U4OiCq NYPIbpI{UUN3ME2wMlA2OcLzMD6wNFgh|ryP Mm\4NlMyOjlyNkW=
SH-SY5Y NH7nfmZCeG:ydH;zbZMhSXO|YYm= NWjp[Ws6OC5zIN88US=> MWGwMVI1KGh? NFLPeWtqdmS3Y3XzJIFxd3C2b4Ppd{Bw\iCVSD3TXVV[KGOnbHzzJIZwdGyxd3nu[{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCC2aHWgS|IwVSCyaHHz[S=> NY\tOJF1OjNzMkmwOlU>
SH-SY5Y NWjWeGg4SXCxcITvd4l{KEG|c3H5 M{jX[FAvOSEQvF2= MX:wMVI1KGh? NXrWWGQycW6mdXPld{BucXSxdHnjJIFzemW|dNMg MXKyN|EzQTB4NR?=

... Click to View More Cell Line Experimental Data

In vivo Vincristine (3 mg/kg) administrated by a single i.p. injection to mice bearing bilateral subcutaneous xenografts Rh12 or Rh18, induces mean growth delay of >120 and >52 day, and repopulating fractions of 0.06% and 5%, respectively. [6] Vincristine acts on subcutaneous colon 38 tumors in mice by host cell-mediated vascular effects as well as by direct tubulin-mediated cytotoxicity. Vincristine (5 mg/kg) reduces tumor blood flow of tumors by nearly 75% . [7]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: B16 melanoma cell
  • Concentrations: 10 nM
  • Incubation Time: 3 days
  • Method: Cells are plated in 2 mL of medium in 35-mm plates at a concentration of about 5 × 104 cells/mL and grow for 24 h at 37 ℃ in an atmosphere of 5% CO2 and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA.
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: Human rhabdomyosarcoma xenografts Rh12
  • Formulation: Water solutioin
  • Dosages: 3 mg/kg
  • Administration: A single i.p. administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (108.33 mM)
Water 60 mg/mL (65.0 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
Saline
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 923.04
Formula

C46H58N4O14S

CAS No. 2068-78-2
Storage powder
Synonyms Leurocristine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03036904 Not yet recruiting Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma Weill Medical College of Cornell University|Genentech, Inc.|Massachusetts General Hospital|M.D. Anderson Cancer Center February 6, 2017 Phase 1
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT03023358 Not yet recruiting Peripheral T Cell Lymphoma Nanfang Hospital of Southern Medical University February 2017 Phase 3
NCT03023046 Not yet recruiting Adult Acute Lymphoblastic Leukemia|Adult Lymphoblastic Lymphoma|CD20 Positive|Philadelphia Chromosome Positive University of Washington|National Cancer Institute (NCI) February 2017 Phase 2
NCT03003520 Recruiting Lymphoma, Large B-Cell, Diffuse Celgene February 2017 Phase 2
NCT03018626 Not yet recruiting Lymphoma, Large B-Cell, Diffuse Nanfang Hospital of Southern Medical University February 2017 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?

  • Answer:

    According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Vincristine sulfate | Vincristine sulfate supplier | purchase Vincristine sulfate | Vincristine sulfate cost | Vincristine sulfate manufacturer | order Vincristine sulfate | Vincristine sulfate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID